Two Phase 3 clinical trials show that risankizumab is effective for achieving skin clearance in patients with psoriasis…
Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis
In a Phase 3 study, ixekizumab proved safe and effective to treat adults with ankylosing spondylitis (AS)…
Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis
In clinical trials, secukinumab proved safe and effective as a long-term treatment for both palmoplantar and nail psoriasis…
Skin Exam Advised Before Anti-TNF-Alpha Therapy
NEW YORK (Reuters Health)—Using tumor necrosis factor alpha (TNF-alpha) inhibitors for atypical dermatoses may unmask, or perhaps even worsen, cutaneous lymphoma, according to new research. “Our findings suggest that careful skin examination might be required in all patients prescribed anti-TNF-alpha agents, especially those with atypical presentations of benign skin conditions,” says Dr. Joan Guitart of…
Bimekizumab Improves Joint & Skin Symptoms in PsA Patients
Preliminary results from an ongoing study show that bimekizumab improves joint and skin symptoms in patients with psoriatic arthritis…
Psoriasis Tied to Higher Risk of Serious Liver Disease
(Reuters Health)—People with chronic inflammatory disorders, such as psoriasis and rheumatoid arthritis (RA), may have an increased risk of developing serious liver damage, a recent study suggests. These inflammatory disorders are often treated with methotrexate, a medication linked to an increased risk of liver disease. For the current study, researchers followed more than 1 million…
Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis
Medications for serious or life-threatening conditions may receive accelerated approval from the U.S. Food and Drug Administration (FDA) by showing an effect on surrogate measures that are reasonably likely to predict a treatment’s clinical benefit. Post-approval confirmatory drug trials are then required to determine whether or not these effects translate into clinical improvements. In recent…
Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis
In October, the FDA approved ustekinumab to treat patients 12 years or older who have moderate to severe plaque psoriasis…
Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
FDA Approves Adalimumab-adbm On Aug. 29, the FDA approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab).1 Cyltezo was approved as a prefilled syringe to treat multiple chronic inflammatory diseases, including moderate to severe active RA, active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been approved for moderate…
Secukinumab Meets 5-Year Benchmark for Psoriasis
In an extension study, nearly half the patients with plaque psoriasis taking secukinumab maintained skin clearance for the five years of the study…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 8
- Next Page »